The Hundred-Dollar Look at Your Death

Dr. Job Mogire, MD, FACP, FACC Board-Certified Cardiologist | Carle Foundation Hospital, Champaign, IL

The coronary artery calcium score is twelve minutes, no needle, no contrast, $100 to $150 out of pocket at most US imaging centers. It produces one number. That number tells you whether coronary atherosclerosis has materialized in your arterial wall.

Not whether it might. Whether it has.

This is the only widely available test that answers that question directly. It is also one of the most underused tests in primary prevention.

What it measures

Atherosclerotic plaque calcifies over time as the body stabilizes it. CT imaging detects that calcium with high sensitivity. The Agatston scoring method quantifies the density and area of each calcified lesion and produces a total score.

A score of zero means no calcified plaque is detectable. This is an anatomical finding. A score of 400 means significant, diffuse calcified plaque is present. This is also an anatomical finding. Neither is a statistical inference.

The MESA evidence

The Multi-Ethnic Study of Atherosclerosis enrolled 6,814 adults without known cardiovascular disease and followed them for approximately 10 years. Key findings from the New England Journal of Medicine established: 5 / Solid

A CAC score of 1 to 10 carried a hazard ratio of 3.66 for coronary events compared to zero, after full adjustment for traditional risk factors. A score above 300 carried event rates comparable to patients with established cardiovascular disease. The CAC score improved risk reclassification significantly over traditional risk factors alone.

The zero finding

A CAC of zero in a man aged 40 to 55 with no major risk features confers a 10-year major cardiovascular event risk below 1 percent. This is lower than the rates traditional risk calculators assign to many intermediate-risk patients. 5 / Solid

The clinical use: the intermediate-risk man who is uncertain about statin therapy. A CAC of zero appropriately defers initiation in many of these cases. A CAC of 280 resolves the uncertainty in the other direction. That is the decision value.

Reading the score

Zero. No detectable plaque. Ten-year risk below 1 percent in appropriate patients. Statin deferral in intermediate-risk patients is reasonable. Repeat at 5 to 7 years.

1 to 99. Mild plaque. Disease has begun. Even a score of 1 to 10 carries a hazard ratio above 3 compared to zero. Risk factor management and statin discussion indicated.

100 to 399. Moderate plaque. Ten-year ASCVD risk typically above 7.5 percent. Statin therapy generally indicated regardless of LDL-C level. Target ApoB under 70 mg/dL.

400 and above. Extensive plaque. Management intensity equivalent to secondary prevention. High-intensity statin, blood pressure treatment, and full risk factor control. Potential further imaging workup as clinically indicated.

What it does not tell you

The CAC score does not measure blockage. A man can have a CAC of 350 with no significantly obstructed artery. The calcium is in the wall, not the lumen.

It does not detect soft plaque. Non-calcified, lipid-rich plaque is invisible to this test. A zero does not guarantee no plaque. This is the most important limitation in younger men.

It is not for everyone. In low-risk individuals below 40 without risk factors, or anyone where the result would not change management, the scan adds nothing.

The Calcification Biology

Calcium does not appear in an artery wall by accident. It is the endpoint of a specific, well-characterized disease process, and understanding that process clarifies what a CAC score actually represents.

Atherosclerosis begins when low-density lipoprotein particles, particularly small and dense LDL and remnant particles, enter the subendothelial space and become oxidized. Macrophages recruited to the site engulf these oxidized lipoproteins and become foam cells. When foam cells die, they release their lipid contents into the arterial wall, forming a necrotic core. This necrotic core is the center of what will become a mature atherosclerotic plaque.

The calcification step happens within that necrotic core. As the core enlarges and becomes more inflammatory, two distinct mechanisms deposit calcium into the tissue. First, matrix vesicles released by dying macrophages and other cells within the plaque initiate nucleation of calcium phosphate crystals, much as they do in bone. Second, and more importantly, vascular smooth muscle cells in the arterial wall undergo a phenotypic transformation: they acquire characteristics of osteoblasts, the bone-forming cells. These transformed smooth muscle cells express osteogenic markers including osteocalcin, osteopontin, and alkaline phosphatase. They actively mineralize the surrounding extracellular matrix.

The result is a calcified lesion within the arterial wall that is chemically similar to bone mineral: hydroxyapatite. CT scanning detects hydroxyapatite with high sensitivity because of its density contrast against surrounding soft tissue.

What this means for interpreting your score: every unit of Agatston score represents a small deposit of mineralized tissue that went through this entire sequence of events. Foam cell accumulation, necrotic core formation, osteogenic transformation, mineralization. A score of 40 is not a risk score. It is anatomical evidence that this process ran to completion at a measurable scale in your coronary arteries.

The calcium is stable compared to the lipid-rich, non-calcified plaque that surrounds it. But the presence of calcified plaque almost always indicates that non-calcified plaque exists in the same territory. The calcium is the visible tip of a broader disease process.

Beyond MESA: Additional Evidence

The MESA data are not the only evidence. Several independent datasets confirm and extend the core findings. 5 / Solid

The CONFIRM registry (Coronary CT Angiography Evaluation For Clinical Outcomes: An International Multicenter Registry) enrolled more than 55,000 patients across multiple international sites and published findings in JAMA in 2012. Hadamitzky and colleagues, along with other CONFIRM investigators, demonstrated that coronary CT angiography findings including calcium burden predicted major cardiovascular events with discrimination superior to clinical risk scores alone. Importantly, the registry confirmed the very low event rate associated with absent or minimal coronary atherosclerosis, consistent with the MESA zero-CAC findings.

Within MESA itself, a specific analysis addressed risk reclassification: the CAC score moved 23 percent of patients originally classified as intermediate risk by Framingham score into either a lower or higher risk category. Reclassification into a higher category was associated with subsequent event rates that justified the more intensive management those patients were then given. Reclassification into a lower category identified men who had been overcounted by traditional risk factor equations.

The Agatston scoring method, developed in 1990 by Arthur Agatston and Warren Janowitz, has been validated against histological plaque burden in autopsy studies. The correlation between the CT-derived calcium score and the actual calcium content measured in coronary arteries at autopsy is strong enough that the Agatston score is now the accepted clinical standard rather than a proxy. The calcium you see on the scan is the calcium in the artery.

The Rotterdam Heart Study, a prospective cohort of Dutch adults followed since the 1990s, independently replicated the MESA finding that CAC is among the strongest predictors of coronary events available in primary prevention. The Heinz Nixdorf Recall Study, a German cohort of 4,814 adults, found that adding CAC to the Framingham risk score improved 10-year risk prediction for myocardial infarction and cardiac death, with a C-statistic improvement from 0.76 to 0.83.

The consistent picture across multiple independent populations: a CAC of zero in an appropriate patient is a powerful, evidence-based signal that warrants genuine clinical weight. A CAC above 100 in the same patient is equally powerful in the other direction.

The Progression Question

A single CAC measurement is a snapshot. The question of what happens when you take two snapshots over time, and what the change in score tells you, is important and more nuanced. 3 / Early

The MESA cohort followed a subset of participants with serial CAC measurements. The data on CAC progression are clinically interesting but should be interpreted with appropriate caution because this is an area of active investigation rather than settled evidence.

The clearest finding: patients who had a CAC of zero at baseline and converted to a positive score over approximately five years had subsequent cardiovascular event rates that looked more like established-CAC patients than like persistent-zero patients. In other words, the “warranty” on a zero score is real. A zero that becomes a 50 over five years represents disease that has crossed a threshold, and the clinical implications follow accordingly.

Annual percentage progression of CAC in patients who already have a positive score has been associated with events, but the relationship is complex. Some data suggest that very rapid progression may carry additional risk beyond what the absolute score predicts. However, the evidence is not strong enough to drive major clinical decisions on progression rate alone, and serial scanning for the purpose of tracking progression is not yet part of standard guideline recommendations.

The practical implication: if you had a CAC of zero at 48 and you are now 54 with the same or worsening risk factor profile, a repeat scan is reasonable. If the score has converted positive, you do not get to use the zero warranty anymore. If it remains zero, the warranty extends.

Serial scanning is not a monitoring tool for men already known to have disease. The management decision at CAC above 100 does not change based on whether the score went from 120 to 160 over five years. Statin therapy, ApoB target, blood pressure control: those remain the priorities, and those are tracked through blood and pressure measurements, not repeat CAC scans.

Soft Plaque: What This Scan Misses

The most important limitation of the CAC score is not the radiation, not the cost, and not the false reassurance in low-risk patients. It is the complete invisibility of non-calcified plaque. 4 / Promising

Non-calcified plaque is lipid-rich and fibrous. It occupies the arterial wall just as calcified plaque does, but it has not yet mineralized. CT scanning without contrast cannot detect it. This matters because non-calcified plaque is the rupture-prone variety.

The PROSPECT trial (Providing Regional Observations to Study Predictors of Events in the Coronary Tree), published in the New England Journal of Medicine in 2011, followed 697 patients with acute coronary syndromes who underwent three-vessel intravascular ultrasound at the time of their index event. The trial tracked which non-culprit lesions later caused events during follow-up. The finding: most subsequent coronary events arose from non-obstructive, non-calcified plaques that would not have been identified by angiography or by CAC scoring. The plaques that ruptured were characterized by large plaque burden, thin fibrous caps, and lipid-rich necrotic cores: the “vulnerable plaque” phenotype.

What this means clinically: a younger man, say 38 to 48 years old, with a high ApoB, insulin resistance, elevated triglycerides, and a family history of premature coronary disease can have substantial non-calcified plaque burden with a CAC of zero. His score is zero not because his arteries are clean but because his disease has not yet mineralized. The atherosclerotic process is active. The necrotic core is forming. The calcium just has not been deposited yet.

This is not a theoretical concern. It is the explanation for sudden cardiac events in men who recently passed a stress test or were told their CAC was reassuringly low.

The clinical response: in younger men with high-risk phenotypes (high ApoB, strong family history, insulin resistance, smoking history), a CAC of zero does not eliminate the need to address modifiable risk factors aggressively. ApoB is the relevant driver of non-calcified plaque accumulation. Getting ApoB below 70 mg/dL in a 42-year-old with a strong family history and a CAC of zero is not excessive. It is appropriate disease-stage management.

The CAC score answers one question precisely. It does not answer all questions about coronary risk.

The Radiation Question

A non-contrast cardiac CT for CAC scoring delivers an effective radiation dose of approximately 1 to 3 millisieverts (mSv). Modern protocols using prospective ECG gating, which images the heart only during a specific phase of the cardiac cycle, routinely achieve doses at or below 1 mSv in lean patients. Some centers with optimized protocols report doses as low as 0.3 to 0.5 mSv.

For context: natural background radiation in the United States is approximately 3 mSv per year from cosmic rays, soil, building materials, and radon. A single CAC scan at 1 to 2 mSv is equivalent to 4 to 8 months of background exposure. A cross-country flight delivers approximately 0.03 to 0.05 mSv. A chest X-ray is approximately 0.1 mSv.

The lifetime attributable risk of cancer from a single 1 to 2 mSv exposure in a 50-year-old man is very small. The National Academies BEIR VII report, using the linear no-threshold model, estimates risks in this range as less than 1 in 10,000 over a lifetime. This must be weighed against the clinical information gained and the cardiovascular events that appropriate management may prevent.

The radiation from this scan is not a meaningful barrier for a man who is a genuine candidate for the test.

Who should have it

The highest-yield candidates:

• Men 40 to 60 with intermediate calculated risk where statin initiation is genuinely uncertain
• Men reluctant to start preventive therapy who need a result to make a clear decision
• Men with a first-degree relative with premature cardiovascular disease
• Men with metabolic syndrome: large waist, elevated triglycerides, low HDL, borderline glucose

Three actions

1. Ask your physician at your next visit: is a coronary artery calcium scan appropriate for me? One question, five minutes.

2. If your score is not zero, bring your ApoB to the conversation. The CAC tells you where you are. ApoB tells you what is still driving the process.

3. If the test has never been raised in your clinical care and you are over 40 with any risk factors, raise it yourself. It is in the AHA/ACC prevention guidelines. It belongs in the conversation.

This paper is educational and does not constitute medical advice. Discuss your individual clinical situation with your physician.